SLC22A5 and cancer: Application of the demethylating agent, DCA, reversed the hypermethylation status of the OCTN2 promoter and increased OCTN2 expression, thereby leading to enhanced uptake of oxaliplatin-causing cancer cells to be more sensitive to oxaliplatin.